Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT: RESP301 for COVID-19 Post-exposure Prophylaxis
NCT04842331Phase 3Withdrawn
- Sponsor
- Thirty Respiratory Limited
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of RESP301 in coronavirus disease 2019 (COVID-19), sponsored by Thirty Respiratory Limited. Planned start Sep 2021; status: withdrawn.
02
Drugs
RESP301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04842331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842331.